Presentation is loading. Please wait.

Presentation is loading. Please wait.

Percentage of patients achieving DAS28 (CRP) < 3

Published bySindre Bråthen Modified over 6 years ago

Similar presentations

Presentation on theme: "Percentage of patients achieving DAS28 (CRP) < 3"— Presentation transcript:

1 Percentage of patients achieving DAS28 (CRP) < 3
Percentage of patients achieving DAS28 (CRP) < 3.2 (A), DAS28 (CRP) < 2.6 (B), CDC (C), and CDR (D) during the course of 10 years of ADA ± MTX treatment. Percentage of patients achieving DAS28 (CRP) < 3.2 (A), DAS28 (CRP) < 2.6 (B), CDC (C), and CDR (D) during the course of 10 years of ADA ± MTX treatment. Lines with symbols represent observed response rate based on all randomized patients (n = 268, 274, and 257 for adalimumab + MTX, adalimumab, and MTX, respectively). Dashed lines represent response rate using nonresponder imputation based on all patients entering open-label extension (n = 183, 159, and 155 for adalimumab + MTX, adalimumab, and MTX, respectively). Bar graphs reflect data as observed at final visit using last observation carried forward method for all randomized patients (n = 268, 274, and 257 for adalimumab + MTX, adalimumab, and MTX, respectively). aSimultaneous achievement of DAS28(CRP) < ΔmTSS ≤ HAQ-DI < 0.5. bSimultaneous achievement of DAS28(CRP) < ΔmTSS ≤ HAQ-DI < 0.5. The CDC and CDR population are patients with radiographic data, nonresponder imputation is used if HAQ or DAS data are missing. ADA: adalimumab; MTX: methotrexate; DAS28: 28-joint Disease Activity Score; CRP: C-reactive protein; HAQ-DI: Health Assessment Questionnaire–Disability Index; ΔmTSS: change in modified total Sharp score. Edward C. Keystone et al. J Rheumatol 2014;41:5-14 ©2014 by The Journal of Rheumatology

Download ppt "Percentage of patients achieving DAS28 (CRP) < 3"

Similar presentations

The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of.

The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of.
Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.

Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.
Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI

Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI
Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.

Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.
Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.

Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.
Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.

Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.
Radiographic progression among three therapy groups (triple therapy group, anti-TNF treatment group and MTX responders) stratified by MBDA categories at.

Radiographic progression among three therapy groups (triple therapy group, anti-TNF treatment group and MTX responders) stratified by MBDA categories at.
Benefit-risk balance. Benefit-risk balance. Predicted probabilities of developing serious infection versus predicted probabilities of achieving Boolean-based.

Benefit-risk balance. Benefit-risk balance. Predicted probabilities of developing serious infection versus predicted probabilities of achieving Boolean-based.
Percentage of patients achieving minimal disease activity (MDA): A

Percentage of patients achieving minimal disease activity (MDA): A
Changes in PMR-AS, CRP levels, and GC dosage (prednisone) following TCZ therapy in 7 patients with PMR. Since our series included patients with long duration.

Changes in PMR-AS, CRP levels, and GC dosage (prednisone) following TCZ therapy in 7 patients with PMR. Since our series included patients with long duration.
Association between anti-CCP antibody status and response to remission, LDA and mACR by anti-CCP status and TNFi initiators (multivariable models). Association.

Association between anti-CCP antibody status and response to remission, LDA and mACR by anti-CCP status and TNFi initiators (multivariable models). Association.
Percentages of (A) ACR 20, 50, and 70 responders, and (B) patients with DAS28-CRP ≤ 3.2 or < 2.6 during 5 years. Percentages of (A) ACR 20, 50, and 70.

Percentages of (A) ACR 20, 50, and 70 responders, and (B) patients with DAS28-CRP ≤ 3.2 or < 2.6 during 5 years. Percentages of (A) ACR 20, 50, and 70.
Updated 2016 PsA Core Domain Set.

Updated 2016 PsA Core Domain Set.
Changes in the proportion (95% CI) of patients with (A) fatal events, (B) serious infections, (C) malignancy, (D) GI perforation, and (E) serious cardiac.

Changes in the proportion (95% CI) of patients with (A) fatal events, (B) serious infections, (C) malignancy, (D) GI perforation, and (E) serious cardiac.
Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis  Kristian Reich,

Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis  Kristian Reich,
Mean DAS (A), HAQ (B) and percentages in low disease activity, DAS remission and drug-free DAS remission (C) during 5 years in the DAS ≤2.4 steered (BeSt)

Mean DAS (A), HAQ (B) and percentages in low disease activity, DAS remission and drug-free DAS remission (C) during 5 years in the DAS ≤2.4 steered (BeSt)
Percentage of patients achieving EULAR response

Percentage of patients achieving EULAR response
Clinical responses over time.

Clinical responses over time.
Efficacy end points: the percentage of patients achieving an improvement in American College of Rheumatology (ACR) of (A) 20% (ACR20), (B) 50% (ACR50)

Efficacy end points: the percentage of patients achieving an improvement in American College of Rheumatology (ACR) of (A) 20% (ACR20), (B) 50% (ACR50)
Association of disease parameters at the time of methotrexate reinitiation during the OLE based on propensity score matching. Association of disease parameters.

Association of disease parameters at the time of methotrexate reinitiation during the OLE based on propensity score matching. Association of disease parameters.

Similar presentations

Ads by Google